These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 23169331)

  • 1. Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
    Palmer M; Chersich M; Moultrie H; Kuhn L; Fairlie L; Meyers T
    AIDS; 2013 Mar; 27(5):781-5. PubMed ID: 23169331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line antiretroviral drug discontinuations in children.
    Fortuin-de Smidt M; de Waal R; Cohen K; Technau KG; Stinson K; Maartens G; Boulle A; Igumbor EU; Davies MA
    PLoS One; 2017; 12(2):e0169762. PubMed ID: 28192529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
    Cassim H; Otwombe K; Lazarus E; Liberty A; Gray GE; Greeff OBW; Violari A
    PLoS One; 2017; 12(7):e0180645. PubMed ID: 28686654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
    Mulenga V; Musiime V; Kekitiinwa A; Cook AD; Abongomera G; Kenny J; Chabala C; Mirembe G; Asiimwe A; Owen-Powell E; Burger D; McIlleron H; Klein N; Chintu C; Thomason MJ; Kityo C; Walker AS; Gibb DM;
    Lancet Infect Dis; 2016 Feb; 16(2):169-79. PubMed ID: 26481928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
    Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa.
    Bonawitz R; Brennan AT; Long L; Heeren T; Maskew M; Sanne I; Fox MP
    Trop Med Int Health; 2018 Jun; 23(6):650-660. PubMed ID: 29656449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
    van Griensven J; Zachariah R; Rasschaert F; Mugabo J; Atté EF; Reid T
    Trans R Soc Trop Med Hyg; 2010 Feb; 104(2):148-53. PubMed ID: 19732926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
    Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
    Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
    Bokore A; Korme B; Bayisa G
    BMC Pharmacol Toxicol; 2018 Jun; 19(1):28. PubMed ID: 29871665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
    Soorju V; Naidoo P
    Afr J Prim Health Care Fam Med; 2016 Oct; 8(1):e1-e6. PubMed ID: 28155312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
    Menezes CN; Crowther NJ; Duarte R; Van Amsterdam D; Evans D; Dickens C; Dix-Peek T; Rassool M; Prinsloo A; Raal F; Sanne I
    HIV Med; 2014 Jan; 15(1):3-12. PubMed ID: 23980620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
    Forna F; Liechty CA; Solberg P; Asiimwe F; Were W; Mermin J; Behumbiize P; Tong T; Brooks JT; Weidle PJ
    J Acquir Immune Defic Syndr; 2007 Apr; 44(4):456-62. PubMed ID: 17279048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
    Elzi L; Marzolini C; Furrer H; Ledergerber B; Cavassini M; Hirschel B; Vernazza P; Bernasconi E; Weber R; Battegay M;
    Arch Intern Med; 2010 Jan; 170(1):57-65. PubMed ID: 20065200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
    Dlamini J; Ledwaba L; Mokwena N; Mokhathi T; Orsega S; Tsoku M; Kowo H; Proschan M; Khabo P; Maja P; Hadigan C
    Antivir Ther; 2011; 16(4):605-9. PubMed ID: 21685549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    HIV Med; 2008 May; 9(5):317-21. PubMed ID: 18331562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recovery from lipodystrophy in HIV-infected children after substitution of stavudine with zidovudine in a non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Aurpibul L; Puthanakit T; Taejaroenkul S; Sirisanthana T; Sirisanthana V
    Pediatr Infect Dis J; 2012 Apr; 31(4):384-8. PubMed ID: 22124211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
    Jaspan HB; Berrisford AE; Boulle AM
    Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
    Manosuthi W; Lueangniyomkul A; Mankatitham W; Chimsuntorn S; Tantanathip P; Thongyen S; Suntisuklappon B; Nilkamhang S; Sungkanuparph S
    J Infect; 2011 May; 62(5):406-9. PubMed ID: 21382413
    [No Abstract]   [Full Text] [Related]  

  • 20. Investigation of the effect of Stalanev (Stavudine, Lamivudine and Nevirapine) treatment on plasma lactate levels in adults attending Beatrice Road and Wilkins Infectious Diseases Hospital Opportunistic Infections Clinics in Harare, Zimbabwe.
    Malunga G; Mujaji WB; Musarurwa C; Nyamayaro T
    Cent Afr J Med; 2012; 58(5-6):22-5. PubMed ID: 26255331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.